GMP IPO Watch
GSP Crop Science IPO Final Day: QIBs Push for Full Subscription while Retail Stays Away
The ₹400 crore GSP Crop Science IPO reaches its conclusion today, March 18, 2026. With institutional (QIB) and high-net-worth (NII) categories already comfortably over the finish line, the total subscription has crossed the 1x mark. However, with a ₹0 Grey Market Premium and a quiet retail segment, we analyze if this is a value-buy for the long term.
Live IPO tracking available
Check GMP movement, allotment details, subscription demand, and deeper IPO context for this company.
Use these shortcuts to keep exploring
The archive button opens all articles from this category. The IPO details button opens the live IPO page on your GMP site in a new tab.
1. The Final Sprint: Subscription Update
As of this morning, the numbers show that "Big Money" has done the heavy lifting.
Overall Subscription: ~1.10x (Expected to surge in the final 2 hours).
QIB (Institutions): 1.35x – Large funds have steadily increased their bids.
NII (HNIs): 2.45x – This is the most active segment, showing strong interest from wealthy private investors.
Retail Individual Investors: 0.22x – Participation from small investors remains surprisingly low, with over 75% of the retail quota still available.
2. Essential Details & Final Deadline
If you are planning a last-minute application, here are the numbers you need:
| Event / Detail | Information |
|---|---|
| Bidding Closes | Today, March 18, 2026 (5:00 PM) |
| Price Band | ₹304 to ₹320 per share |
| Minimum Lot Size | 46 Shares |
| Min. Investment | ₹14,720 |
| Allotment Status | Friday, March 20, 2026 |
| Listing Date | Tuesday, March 24, 2026 (NSE & BSE) |
3. The GMP Reality Check
The Grey Market Premium (GMP) remains at ₹0.
The "Flat" Signal: This indicates that the unofficial market expects the stock to list exactly at its issue price of ₹320.
Why the Silence? The agrochemical sector is currently facing global headwinds due to potential El Niño concerns for the 2026 monsoon. Short-term "flippers" are avoiding the issue because there is no immediate "listing pop" in sight.
4. The "Value" Argument: Is it Underpriced?
While the GMP is cold, the fundamentals tell a warmer story. Most brokerages have given a "Subscribe for Long Term" rating based on valuation:
PE Ratio: At ₹320, GSP is priced at 15.3x.
Industry Comparison: Compare this to industry peers like Sumitomo Chemical (~39x) or Dhanuka Agritech (~22x).
The "Catch-Up" Potential: GSP is entering the market at a significant discount to its peers, which could lead to steady growth once the market stabilizes.
5. Financials: The 2026 Outlook
GSP’s strength lies in its transition from a generic manufacturer to a patent-holder.
Profitability: They reported a net profit of ₹81.4 Crore for FY25.
Half-Yearly Surge: For the first half of the current year (H1 FY26), they have already hit ₹81 Crore, nearly matching their entire previous year's performance in just six months.
Debt Reduction: The ₹170 crore earmarked for debt repayment will significantly lower interest costs starting next quarter.
6. Final Verdict: To Bid or Not?
Apply If:
You are a long-term investor looking for a high-ROE (35%+) company at a reasonable price.
You believe in the "Make in India" agrochemical story and are comfortable with the cyclical nature of farming.
Avoid If:
You are looking for listing day gains. Current signals suggest the stock will list near its offer price.
You are worried about monsoon volatility impacting the 2026 crop cycle.
